Becton, Dickinson and Company (NYSE:BDX) Director Jeffrey William Henderson Acquires 1,500 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were acquired at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now owns 8,015 shares in the company, valued at approximately $1,872,464.30. This represents a 23.02 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of NYSE BDX opened at $229.35 on Tuesday. The firm’s 50 day moving average price is $232.07 and its 200-day moving average price is $234.02. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13. The company has a market cap of $66.51 billion, a PE ratio of 38.10, a P/E/G ratio of 1.65 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its stake in shares of Becton, Dickinson and Company by 0.6% in the 3rd quarter. CWM LLC now owns 8,965 shares of the medical instruments supplier’s stock worth $2,161,000 after purchasing an additional 57 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its position in Becton, Dickinson and Company by 429.2% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,466 shares of the medical instruments supplier’s stock worth $594,000 after acquiring an additional 2,000 shares during the period. First Affirmative Financial Network boosted its stake in shares of Becton, Dickinson and Company by 11.9% during the 3rd quarter. First Affirmative Financial Network now owns 1,226 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 130 shares during the last quarter. Matrix Asset Advisors Inc. NY grew its position in shares of Becton, Dickinson and Company by 37.6% during the 3rd quarter. Matrix Asset Advisors Inc. NY now owns 35,295 shares of the medical instruments supplier’s stock valued at $8,510,000 after acquiring an additional 9,645 shares during the period. Finally, Cardinal Capital Management Inc. purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $30,089,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research reports. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.